Aralez Pharmaceuticals Inc. (ARLZ) is a publicly traded company in the Unknown sector. Across all available filings, 17 corporate insiders have executed 102 transactions totaling $21.6M, demonstrating a bearish sentiment with -$13.3M in net insider flow. The most recent transaction on Jun 4, 2018 involved a sale of 156,573 shares valued at $57.9K.
No significant insider buying has been recorded for ARLZ in the recent period.
No significant insider selling has been recorded for ARLZ in the recent period.
Based on recent SEC filings, insider sentiment for ARLZ is bearish with an Insider Alignment Score of 19/100 and a net flow of -$13.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Aralez Pharmaceuticals Inc. (ARLZ) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 17 insiders are actively trading ARLZ stock, having executed 102 transactions in the past 90 days. The most active insider is Inc/bc Qlt (Executive), who has made 1 transactions totaling $15.0M.
Get notified when executives and directors at ARLZ file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 4, 2018 | I. Koven Andrew | Executive | Sale | 156,573 | $0.37 | $57.9K | |
| May 14, 2018 | Patrick Tursi James | Executive | Sale | 9,348 | $0.52 | $4.9K | |
| May 14, 2018 | I. Koven Andrew | Executive | Sale | 13,964 | $0.52 | $7.3K | |
| Mar 19, 2018 | A. Glickman Mark | Executive | Sale | 5,725 | $1.70 | $9.7K | |
| Mar 19, 2018 | I. Koven Andrew | Executive | Sale | 9,739 | $1.70 | $16.6K | |
| Mar 19, 2018 | Patrick Tursi James | Executive | Sale | 5,950 | $1.70 | $10.1K | |
| Mar 19, 2018 | Trachtenberg Eric | Executive | Sale | 3,471 | $1.70 | $5.9K | |
| Mar 15, 2018 | Kaseta Michael | Executive | Award | 12,500 | $N/A | $0 | |
| Dec 8, 2017 | S. Kirsch Arthur | Executive | Purchase | 50,000 | $1.47 | $73.5K | |
| Oct 2, 2017 | Patrick Tursi James | Executive | Sale | 9,960 | $2.50 | $24.9K | |
| Jul 28, 2017 | J. Charles Scott | Executive | Sale | 10,804 | $1.25 | $13.5K | |
| Jun 23, 2017 | Trachtenberg Eric | Executive | Sale | 7,720 | $1.33 | $10.3K | |
| Jun 15, 2017 | S. Kirsch Arthur | Executive | Purchase | 15,000 | $1.15 | $17.3K | |
| Jun 14, 2017 | S. Kirsch Arthur | Executive | Purchase | 50,000 | $1.17 | $58.5K | |
| Jun 5, 2017 | I. Koven Andrew | Executive | Sale | 161,906 | $1.28 | $207.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 21 | $17.4M | 75.4% |
Purchase(P) | 21 | $4.2M | 18.1% |
Payment(F) | 7 | $980.5K | 4.2% |
Exercise(M) | 5 | $541.9K | 2.3% |
Award(A) | 34 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Other(J) | 12 | $0 | 0.0% |
Insider selling pressure at Aralez Pharmaceuticals Inc. has increased, with 17 insiders executing 102 transactions across all time. Total sales of $17.4M significantly outpace purchases of $4.2M, resulting in a net outflow of $13.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.